Search
rubella virus vaccine, live (Meruvax II)
Indications: vaccine-induced immunity to rubella
Contraindications:
1) hypersensitivity to neomycin
2) pregnancy
3) patients receiving immunosuppressive agents
4) patients receiving radiation therapy
Caution:
1) females should avoid pregnancy for 3 months afer vaccination
2) defer vaccination for 3 months following plasma transfusions or administration of immune globulin or immunosuppressive drugs
Dosage:
Injection: 1000 TCID50 of rubella (Wistar RA 27/3 Strain)
Adverse effects:
1) common (> 10%)
- arthralgias
- local tenderness & erythema
- urticaria
- rash
- joint pain 1-10 weeks after vaccination, persisting 1-3 days
2) less common (1-10%)
- malaise, fever, headache, sore throat, lymphadenopathy
3) uncommon (< 1%)
- hypersensitivity, allergic reactions to vaccine, optic neuritis
Test interactions:
- temporary suppression of TB skin test reactivity
Related
measles & rubella combined vaccine (M-R-VAX II)
measles, mumps & rubella combined vaccine (MMR)
rubella (German measles, 3rd disease)
General
live virus vaccine
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Department of Veterans Affairs, VA National Formulary
Component-of
measles virus vaccine live attenuated/mumps virus vaccine/rubella virus vaccine live
measles virus vaccine live attenuated/mumps virus vaccine/rubella virus vaccine live/varicella virus vaccine
measles virus vaccine live attenuated/rubella virus vaccine live